In contrast, ruxolitinib, an inhibitor of JAK1 and JAK2, has been tested in mouse models of HLH and found to promote survival and reduce levels of pro-inflammatory cytokines IL-6 and TNFα81,82, suggesting that JAK1/2 may be a therapeutic target in patients with HLH. The gene discussed is JAK2; the disease is hemophagocytic syndrome.